Caribou Biosciences, Inc.
CRBU- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001619856
No open-market purchases or sales by Caribou Biosciences, Inc. insiders were filed in the last 90 days; 137 institutions reported holding it in 13F filings for Q2 2026, worth $85.4M in total; Maverick Capital is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +1 vs. previous quarter
- 137
- 13F valueReported value at the end of Q2 2026
- $85.4M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding CRBU, Q2 2026
1 superinvestor reports holding Caribou Biosciences, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Maverick Capital
Lee Ainslie
<0.1%
Caribou Biosciences, Inc.'s share of the portfolio
- Shares
- 652,542
- Value
- $1.15M
Latest insider trades
Open-market purchases and sales by Caribou Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 (view filing) | Feb 25 | 2 days | Kelly Timothy PChief Technology Officer | SSale | −6.23K | $1.93 | −$12.0K | −7.8%73.1K after | |
| Feb 24, 2026 (view filing) | Feb 24 | Same day | Albertson Tina M.Chief Medical Officer | SSale | −1.07K | $1.96 | −$2.09K | −1.5%68.5K after | 10b5-1 |
| Feb 24, 2026 (view filing) | Feb 24 | Same day | Khan Ruhi AhmadChief Business Officer | SSale | −6.94K | $1.96 | −$13.6K | −6.2%105.0K after | |
| Feb 24, 2026 (view filing) | Feb 24 | Same day | Kelly Timothy PChief Technology Officer | SSale | −3.15K | $1.96 | −$6.17K | −3.8%79.4K after | |
| Feb 24, 2026 (view filing) | Feb 24 | Same day | McClung Barbara GChief Legal Officer | SSale | −6.94K | $1.96 | −$13.6K | −1.4%481.6K after | |
| Mar 17, 2025 (view filing) | Mar 14 | 3 days | Haurwitz Rachel E.President and CEO | PPurchase | +20.0K | $1.02 | +$20.4K | +0.6%3.37M after | |
| Feb 21, 2025 (view filing) | Feb 21 | Same day | Khan Ruhi AhmadChief Business Officer | SSale | −3.56K | $1.35 | −$4.81K | −5.1%66.9K after | |
| Feb 21, 2025 (view filing) | Feb 21 | Same day | Kanner StevenChief Scientific Officer | SSale | −3.56K | $1.35 | −$4.81K | −0.8%431.6K after | |
| Feb 21, 2025 (view filing) | Feb 21 | Same day | McClung Barbara GChief Legal Officer | SSale | −3.56K | $1.35 | −$4.81K | −0.8%443.5K after | |
| Jan 30, 2025 (view filing) | Jan 29 | 1 day | Ryali SriramChief Financial Officer | PPurchase | +17.4K | $1.42 | +$24.7K | New position17.4K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Caribou Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,815,843 | $13.8M | 0.00% | +5,672,758+264.7% | Added |
| Pfizer Inc | 4,690,431 | $7.88M | 4.63% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 4,208,568 | $7.41M | 0.00% | +441,340+11.7% | Added |
| Mackenzie Financial Corp | 3,650,796 | $6.43M | 0.01% | +2,708,010+287.2% | Added |
| Renaissance Technologies LLC | 2,773,545 | $4.88M | 0.01% | +183,048+7.1% | Added |
| Kynam Capital Management, LP | 2,503,302 | $4.41M | 0.24% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 2,374,894 | $4.18M | 0.00% | +1,356,935+133.3% | Added |
| Acadian Asset Management LLC | 1,774,474 | $3.12M | 0.00% | +849,435+91.8% | Added |
| State Street Corp | 1,632,914 | $2.87M | 0.00% | +1,209,651+285.8% | Added |
| Bank of America Corp | 1,410,958 | $2.48M | 0.00% | +113,791+8.8% | Added |